Summary

US Acinetobacter Pneumonia Therapeutics Market is valued at approximately USD 91.26 million in 2023 and is anticipated to grow with a healthy growth rate of more than 6.42% over the forecast period 2024-2032. Acinetobacter pneumonia therapeutics is a pharmacological interventions and treatment strategies designed to address pneumonia caused by Acinetobacter baumannii, a gram-negative bacterium notorious for its resistance to various antibiotics. The treatment entails a combination of antimicrobial agents tailored to the susceptibility profile of the infecting strain, supplemented by supportive measures to manage associated complication. The United States surpasses other regions in healthcare spending per capita, thereby augmenting the accessibility of novel and high-cost drugs. The presence of prominent pharmaceutical companies supported by significant research and development allocations further catalyzes innovation and the development of new pneumonia drugs contributing towards the growth of US Acinetobacter Pneumonia Therapeutics Market.

The growing demand of the US Acinetobacter Pneumonia Therapeutics market is propelled by the expanding incidence of Acinetobacter pneumonia bacterial infection, limited approved therapies, and a restricted antibacterial pipeline. Moreover, the US Acinetobacter pneumonia therapeutics market is witnessing a significant shift towards preventive healthcare as a primary driver. Heightened awareness emphasizes prevention over curative approaches, resulting in a growing demand for strategies aimed at averting the onset of this condition. Regulatory requirements for Acinetobacter pneumonia therapeutics, especially in the development of new antibiotics, are becoming increasingly stringent. Challenges such as the rapid emergence of antimicrobial resistance, limited detection of genetic resistance mechanisms, and difficulties in drug penetration into pulmonary tissues are prominent. Given the limited options in antibiotics, alternative strategies like peptides and nanoparticles play a crucial role, highlighting the necessity for innovation to combat antimicrobial resistance, thereby posing a challenge for the US Acinetobacter pneumonia therapeutics market.

Major market player included in this report are:
Pfizer Inc.
Merck & Co., Inc.
Johnson & Johnson Services Inc
AbbVie Inc.
Company 5
Company 6
Company 7
Company 8
Company 9
Company 10

The detailed segments and sub-segment of the market are explained below:

By Drug Class
Cephalosporins
Fluoroquinolone
Glycylcycline
Carbapenem
β-Lactam antibiotics
Sulbactam
Aminoglycoside
Polymyxins
Tetracycline
Sulfonamide
Others
By Route of Administration
Parenteral
Oral
Others

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

ページTOPに戻る

Table of Contents

Chapter 1. US Acinetobacter Pneumonia Therapeutics Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Acinetobacter Pneumonia Therapeutics Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Drug Class
2.2.2. By Route of Administration
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Acinetobacter Pneumonia Therapeutics Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Acinetobacter Pneumonia Therapeutics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Acinetobacter Pneumonia Therapeutics Market Size & Forecasts by Drug Class 2022-2032
5.1. Cephalosporins
5.2. Fluoroquinolone
5.3. Glycylcycline
5.4. Carbapenem
5.5. β-Lactam antibiotics
5.6. Sulbactam
5.7. Aminoglycoside
5.8. Polymyxins
5.9. Tetracycline
5.10. Sulfonamide
5.11. Others
Chapter 6. US Acinetobacter Pneumonia Therapeutics Market Size & Forecasts by Route of Administration 2022-2032
6.1. Parental
6.2. Oral
6.3. Others
Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Pfizer Inc.
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Market Strategies
7.3.2. Merck & Co., Inc.
7.3.3. Johnson & Johnson Service Inc.
7.3.4. AbbVie Inc.
7.3.5. Company 5
7.3.6. Company 6
7.3.7. Company 7
7.3.8. Company 8
7.3.9. Company 9
7.3.10. Company 10
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes